Affinity Asset Advisors »

Evommune shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Evommune (EVMN) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Evommune

Tip: Access up to 7 years of quarterly data

All positions including Evommune held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Evommune by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2026-06-30 $6.6M 500k 13.29

More positions owned by Affinity Asset Advisors

Roivant Sciences SHS (ROIV)
Apogee Therapeutics (APGE)
Spyre Therapeutics Com New (SYRE)
Xenon Pharmaceuticals (XENE)
Erasca (ERAS)
Alkermes SHS (ALKS)
Insmed Com Par $.01 (INSM)
Moderna Put Option (MRNA)
Praxis Precision Medicines I Com New (PRAX)
Oruka Therapeutics (ORKA)
Anaptysbio Inc Common (ANAB)
Avalo Therapeutics Com New (AVTX)
Cytokinetics Com New (CYTK)
Revolution Medicines (RVMD)
Abivax Sa Sponsored Ads (ABVX)

View all positions for Affinity Asset Advisors

Top funds holding Evommune

EQT Fund Management S.a r.l.
RA Capital Management
Pivotal bioVenture Partners Investment Advisor
Jpmorgan Chase & Co
Rtw Investments
Nan Fung Group Holdings
Point72 Asset Management
Andera Partners
SymBiosis Capital Partners
Eventide Asset Management
T. Rowe Price Associates
Vestal Point Capital
Henderson Group
Jupiter Topco
BlackRock

View all funds holding Evommune